Genetic Testing and the Path to a Diagnosis
At a Glance
COMNB is confirmed by finding disease-causing variants in both copies of the SLC5A6 gene, usually through whole exome or genome sequencing. Blood and urine markers can resemble biotinidase deficiency, so enzyme activity and specialist interpretation are important.
Getting to a diagnosis for COMNB is often a complex journey. Because it is incredibly rare, its biochemical markers frequently mimic other metabolic conditions [1]. Understanding how the genetics work and why certain tests are used can help you feel more confident in your child’s care plan.
The Genetics of COMNB: Autosomal Recessive Inheritance
Your child’s condition is inherited in an autosomal recessive pattern [2]. This means that for the condition to occur, a child must inherit two non-working copies of the SLC5A6 gene—one from each parent [3].
- Biallelic Variants: This is the medical term for having a pathogenic change (variant) in both copies of the gene [2].
- Carriers: In most cases, each parent is a “carrier.” Carriers have one working copy and one non-working copy of the gene. They typically have no symptoms because the single working copy provides enough transporter function for the body [3].
- Inheritance Risk: When two carriers have a child, there is a 25% chance in each independent pregnancy that the child will inherit two non-working copies and have the condition. There is a 50% chance they will be a carrier, and a 25% chance they will not carry the variant at all. Genetic counseling is highly recommended for parents and siblings.
The “Great Mimic”: Why Blood and Urine Tests Can Be Confusing
One of the biggest challenges in diagnosing COMNB is that routine metabolic tests can look almost identical to biotinidase deficiency (a more common, distinct metabolic disorder) [1].
Biochemical Mimicry
When a doctor looks at your child’s blood and urine, they may see high levels of certain byproducts, such as C3 and C5-OH acylcarnitines or urinary 3-hydroxyisovaleric acid (3-HIA) [4]. Normally, these markers raise suspicion for biotinidase deficiency [1].
However, there is a key functional difference:
- In biotinidase deficiency, the body cannot recycle free biotin properly because a specific enzyme is impaired.
- In COMNB, the body has the enzyme, but the nutrients cannot adequately cross into the cells [5].
Because the cells lack intracellular biotin, the lab results show the same high acid levels as if the biotin were missing entirely [1]. However, when doctors test the biotinidase enzyme activity itself, they find it is normal or only slightly reduced [4]. This enzyme result is often the crucial clue that the problem is actually a transport defect like COMNB [5]. Keep in mind that these markers (C3, C5-OH, 3-HIA) are not perfectly specific to SLC5A6; they can fluctuate based on fasting, illness, diet, and renal function.
Definitive Diagnostic Tests
Because biochemical tests alone are not definitive, doctors rely on advanced genetic analysis.
Genetic Sequencing (WES/WGS)
A diagnosis typically requires Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) [6]. These tests analyze your child’s genetic code to find the specific biallelic variants in the SLC5A6 gene [1]. While powerful, even WES/WGS can miss certain deep intronic or structural variants, so interpretation must be done by a clinical genetics team [3].
Fibroblast Biotin Uptake Assay
Sometimes, genetic testing finds a “Variant of Uncertain Significance” (VUS). This means a change was found, but the laboratory does not have enough evidence to know if it causes disease. In these cases, doctors may order a fibroblast biotin uptake assay [3].
- A small sample of skin cells (fibroblasts) is cultured in a lab.
- Scientists measure exactly how much biotin those cells pull inside.
- In some children with COMNB, the uptake of biotin is significantly reduced (e.g., ~90% lower than healthy cells). This provides strong supporting evidence to help geneticists classify the VUS, though it does not single-handedly “prove” a diagnosis [3].
Ruling Out Other Conditions (Differential Diagnosis)
Before confirming COMNB, your medical team will likely evaluate for other “look-alike” conditions that are also treatable:
- Riboflavin Transporter Deficiency (RTD): Also known as Brown-Vialetto-Van Laere syndrome. This can cause similar progressive nerve problems but often includes hearing loss or respiratory difficulties. It is treated with riboflavin (Vitamin B2) [7][8].
- Biotinidase Deficiency: Confirmed by low enzyme activity and treated with biotin [9].
- Holocarboxylase Synthetase Deficiency: Another disorder that typically presents very early in infancy with severe metabolic issues [10].
Distinguishing between these is vital because the specific, specialist-directed combination of supplements needed for COMNB is unique to the SLC5A6 defect [3].
Common questions in this guide
How is COMNB confirmed?
Why can COMNB look like biotinidase deficiency on laboratory tests?
What does autosomal recessive inheritance mean for my child and our family?
What is a fibroblast biotin uptake assay?
What other conditions may doctors rule out before diagnosing COMNB?
Can blood and urine markers alone diagnose COMNB?
Get notified when new evidence is published on peripheral motor neuropathy, childhood-onset, biotin-responsive.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (10)
- 1
Genetic defect of the sodium-dependent multivitamin transporter: A treatable disease, mimicking biotinidase deficiency.
Schwantje M, de Sain-van der Velden M, Jans J, et al.
JIMD reports 2019; (48(1)):11-14 doi:10.1002/jmd2.12040.
PMID: 31392107 - 2
Novel missense variants cause intermediate phenotypes in the phenotypic spectrum of SLC5A6-related disorders.
Utsuno Y, Hamada K, Hamanaka K, et al.
Journal of human genetics 2024; (69(2)):69-77 doi:10.1038/s10038-023-01206-5.
PMID: 38012394 - 3
Genome sequencing enables diagnosis and treatment of SLC5A6 neuropathy.
Riley LG, Sabui S, Said HM, et al.
European journal of human genetics : EJHG 2024; (32(8)):947-953 doi:10.1038/s41431-024-01641-8.
PMID: 38816490 - 4
A new case of sodium-dependent multivitamin transporter defect occurring as a life-threatening condition responsive to early vitamin supplementation and literature review.
Van Vyve FX, Mercier N, Papadopoulos J, et al.
Molecular genetics & genomic medicine 2024; (12(2)):e2388 doi:10.1002/mgg3.2388.
PMID: 38407570 - 5
Molecular Mechanisms of Biotin in Modulating Inflammatory Diseases.
Sakurai-Yageta M, Suzuki Y
Nutrients 2024; (16(15)) doi:10.3390/nu16152444.
PMID: 39125325 - 6
Prenatal Brain Abnormalities in Sodium-Dependent Multivitamin Transporter Deficiency.
Ogawa E, Kosaki K, Takenouchi T
American journal of medical genetics. Part A 2025; (197(9)):e64102 doi:10.1002/ajmg.a.64102.
PMID: 40272030 - 7
Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience.
Jaeger B, Bosch AM
Journal of inherited metabolic disease 2016; (39(4)):559-64 doi:10.1007/s10545-016-9924-2.
PMID: 26973221 - 8
Genetic, Radiologic, and Clinical Variability in Brown-Vialetto-van Laere Syndrome.
Woodcock IR, Menezes MP, Coleman L, et al.
Seminars in pediatric neurology 2018; (26()):2-9 doi:10.1016/j.spen.2017.03.001.
PMID: 29961509 - 9
Biotinidase deficiency: What have we learned in forty years?
Tankeu AT, Van Winckel G, Elmers J, et al.
Molecular genetics and metabolism 2023; (138(4)):107560 doi:10.1016/j.ymgme.2023.107560.
PMID: 37027963 - 10
Biotin Homeostasis and Human Disorders: Recent Findings and Perspectives.
Karachaliou CE, Livaniou E
International journal of molecular sciences 2024; (25(12)) doi:10.3390/ijms25126578.
PMID: 38928282
This page explains genetic and biochemical testing for COMNB for educational purposes and does not replace medical advice. A clinical genetics or metabolic specialist should interpret your child's results and guide testing.